Atwood Oceanics, Inc., an offshore drilling contractor, engages in the drilling and completion of exploratory and developmental oil and gas wells. As of November 11, 2016, it owned a fleet of 10 mobile offshore drilling units. The company operates its fleet in the United States, Gulf of Mexico, the Mediterranean Sea, offshore West Africa, offshore Southeast Asia, and offshore Australia. Atwood Oceanics, Inc. was founded in 1968 and is headquartered in Houston, Texas.

2u partners with leading colleges and universities to deliver the world’s best online degree programs so students everywhere can reach their full potential. our platform, a fusion of cloud-based software-as-a-service technology and technology-enabled services, provides schools with the comprehensive operating infrastructure they need to attract, enroll, educate, support and graduate students globally. blending live face-to-face classes, dynamic course content and real-world learning experiences, 2u’s no back row® approach ensures that every qualified student can experience the highest quality university education for the most successful outcome. to learn more, go to 2u.com. be sure to follow us on twitter (twitter.com/2uinc), instagram (http://instagram.com/2uinc) and facebook (facebook.com/2u).

acadia is a provider of inpatient and outpatient behavioral health and addiction treatment services. acadia operates a network of 225 behavioral healthcare facilities with approximately 9,190 beds in 37 states, the united kingdom and puerto rico. acadia provides psychiatric and chemical dependency services to its patients in a variety of settings, including inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and therapeutic school-based programs. acadia healthcare’s behavioral health treatment facilities are specialized solely in helping children, teenagers and adults suffering from mental health disorders and/or alcohol and drug addiction.

advanced energy has devoted more than three decades to perfecting power—enabling design breakthroughs and driving growth for leading semiconductor and industrial customers. our precision power and control technologies, along with our applications know-how, inspire close partnerships and perpetual innovation in thin-film and industrial manufacturing. founded in 1981, advanced energy has built a diversified and global business, delivering advanced power and control technologies to customers across a broad range of industries. the ae team, deployed throughout north america, europe, and asia, provides technical expertise and responsive and agile power solutions for thin-film and industrial manufacturing.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.

agilysys is a leading developer and marketer of proprietary enterprise software, services and solutions to the hospitality industry. the company specializes in market-leading point-of-sale, property management, inventory & procurement, workforce management and mobile & wireless solutions that are designed to streamline operations, improve efficiency and enhance the guest experience. agilysys serves casinos, resorts, hotels, foodservice venues, stadiums and cruise lines. agilysys operates extensively throughout north america, europe and asia, with corporate services located in alpharetta, ga, and apac offices in singapore, hong kong and malaysia. for more information, visit www.agilysys.com. follow us on twitter @agilysys

at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

allscripts (nasdaq: mdrx) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. our innovative solutions connect people, places and data across an open, connected community of health™. connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. to learn more, visit www.allscripts.com, twitter, youtube and blog.allscripts.com.